Erythropoietin directly stimulates osteoclast precursors and induces bone loss

FASEB J. 2015 Jan 28. pii: fj.14-259085. [Epub ahead of print]

In summary, our findings demonstrate that EPO negatively regulates bone mass and thus bears significant clinical implications for the potential management of patients with endogenously or therapeutically elevated EPO levels.

Autor: Hiram S,Liron T,Desher N,Mittelman M,Gassmann M,Rauner M,Franke K,Wielockx B,Neumann D,Gabet
Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Gebro